Alimentary Pharmacology & Therapeutics

Papers
(The H4-Index of Alimentary Pharmacology & Therapeutics is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Editorial: Endomysial Antibodies for a No‐Biopsy Diagnosis of Coeliac Disease—The Jury Is Still out. Authors' Reply191
Issue Information141
AP&T: Editors' Declarations of Interest129
Editorial: Breath Profiling in MASLD—A Step Towards Better Risk Stratification118
Issue Information115
108
Letter: Positivity of High‐Sensitivity HBsAg Test Was Significantly Associated With Poor Prognosis in Patients With Non‐HBV‐Related HCC101
Editorial: Implementing Risk Assessment Tools for MetALD in Clinical Practice—Authors' Reply86
Letter: Gut microbiota—An overlooked therapeutic target in the prevention of post‐operative recurrence of Crohn's disease86
Letter: Supporting the Role of Enzyme Therapy in Management of Coeliac Disease80
Letter: Double PBC ‐Related Autoantibody Positivity—How Essential Is It for Diagnosis? Authors' Reply79
Systematic Review: Variability in Definitions of Fibrostenosis in Eosinophilic Oesophagitis77
Cost‐effectiveness of an adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease71
69
Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises Importance of Appropriate Patient Selection and Centre Expertise—Authors' Rep68
Clinical Trial: Association Between Early Disease Clearance and Long‐Term Outcomes—4‐Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis64
Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis61
Liver resection versus microwave ablation for hepatocellular carcinoma in ideal candidates for ablation per Barcelona Clinic Liver Cancer staging: a propensity score matching and inverse probability o59
Clinical Trial: Effect of Abdominal Vibration Combined With Walking Exercise Programme on Bowel Preparation in Older Patients With Constipation57
Prevalence and clinical characteristics of patients with metabolic dysfunction‐associated fatty liver disease with hepatitis C virus infection—a population‐based study57
First in human randomised trial of J2H‐1702: A novel 11β‐hydroxysteroid dehydrogenase type 1 inhibitor for non‐alcoholic steatohepatitis treatment56
Letter: time to consider Pneumocystis jirovecii pneumonia prophylaxis in treatment of autoimmune hepatitis55
Affinity Proteomics‐Based Non‐Invasive Detection of Clinically Significant Liver Disease55
Letter: Thiopurines the Silent Workhorse for Many Patients After a Flare of Ulcerative Colitis. Authors' Reply55
Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis54
Issue Information52
52
Positivity of high‐sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non‐HBV‐related HCC51
Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply51
Letter: Allostatic load—A potential key in the development of inflammatory bowel disease51
Letter: Elderly onset inflammatory bowel disease—Treat to target approach is still warranted51
Editorial: tradipitant has promise for treating gastroparesis but leaves gastric function alone—authors’ reply50
Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues‐treated patients with chronic hepatitis B50
Editorial: rectal hyposensitivity in patients with hypermobile Ehlers‐Danlos syndrome and constipation—authors' reply49
Letter: ductular reaction is a risk factor for prognosis of chronic hepatitis B complicated with non‐alcoholic fatty liver disease48
Editorial: ustekinumab during pregnancy ‐ reassuring but still not enough48
Editorial: Plants against animals48
Letter: Ozanimod and latent tuberculosis47
Editorial: coeliac disease follow‐up guided by gluten immunogenic peptides—are we there yet? Authors' reply45
Editorial: concurrence of coeliac disease with inflammatory bowel disease – is big data the final arbiter? Authors' reply44
Letter: practical considerations for nonselective beta‐blocker therapy in portal hypertension43
Editorial: Advanced glycation end products ‐ a dietary culprit for IBD in the genetically susceptible?43
0.079971075057983